Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trialResearch in context

Summary: Background: Frontotemporal dementia (FTD) is a common form of dementia with no approved pharmacological treatment. Clinical and experimental evidence suggest that dopaminergic transmission is impaired in FTD. Here we aimed at investigating the clinical impact of treatment with dopaminergic...

Descripció completa

Dades bibliogràfiques

Autors principals:	Giacomo Koch, Martina Assogna, Yasmine Gadola, Antonella Alberici, Francesco Di Lorenzo, Sonia Bonnì, Ilaria Borghi, Emanuele Cerulli Irelli, Lucia Mencarelli, Michele Maiella, Romina Esposito, Elias Paolo Casula, Valentina Pezzopane, Alessia D'Acunto, Francesca Candeo, Matteo Ferraresi, Gisella Guerrera, Luca Battistini, Enrico Premi, Valeria Bracca, Silvia Lucchini, Francesco Bertagna, Pasquale Romano, Andrea Ludovici, Antonio Daniele, Caterina Motta, Clarissa Ferrari, Alessandro Martorana, Barbara Borroni
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-10-01
Col·lecció:	The Lancet Regional Health. Europe
Matèries:	Frontotemporal dementia Rotigotine Executive function Neurotransmission deficit Dopamine
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2666776225002017
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!